Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories specified Items Impact on Diluted EPS ($/share) ($)
Form 8-K Non-GAAP Reconciliation Tables
Latest, FY2025
1.43
Period ended Dec 31, 2025
Change on a year earlier
–
History
4 years
Since FY2021
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Specified Items Impact on Diluted EPS ($/share) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.43 | – | SEC Filing (0001628280-26-002982) ↗ |
| FY2023 | Dec 31, 2023 | 1.18 | -17.5% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 1.43 | +12.6% | SEC Filing (0001628280-24-002009) ↗ |
| FY2021 | Dec 31, 2021 | 1.27 | – | SEC Filing (0001628280-23-001516) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Specified Items Impact on Diluted EPS ($/share) ($), annual FY2021–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/spec-eps-diluted
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.